Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study of the Efficacy and Safety of PEGylated Recombinant Human Growth Hormone Injection in the Treatment of Short Stature in Chinese Children From the Global Registry for Novel Therapies For Rare Bone or Endocrine Conditions

NCT06037473 is registered in ClinicalTrials.gov with Beijing Children's Hospital as lead sponsor.

NCT NCT06037473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06037473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study of the Efficacy and Safety of PEGylated Recombinant Human Growth Hormone Injection in the Treatment of Short Stature in Chinese Children From the Global Registry for Novel Therapies For Rare Bone or Endocrine Conditions
Lead sponsor
Beijing Children's Hospital
Phase
Observational
Overall status
Recruiting
Start date
August 1, 2023
Completion date
August 1, 2029
Enrollment
2,600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

growth disorders, growth hormone treatment